Apellis Pharmaceuticals, Inc. is a company in the U.S. stock market and it is a holding in 34 U.S.-traded ETFs. APLS has around 5.6M shares in the U.S. ETF market. The largest ETF holder of APLS is the SPDR S&P Biotech ETF (XBI), with approximately 1.85M shares. Investors may also find of interest that the ETF with the largest allocation to APLS stock is ALPS Medical Breakthroughs ETF (SBIO), with a portfolio weight of 1.66%. On average, U.S. ETFs allocate 0.22% of APLS to their portfolios.
Additionally, APLS is a favorite stock for Vanilla and Equal ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with APLS as a holding is the Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a return of 50.29%.